H-Index
70
Scimago Lab
powered by Scopus
Clarivate
Analytics
Formerly the IP & Science
business of Thomson Reuters

Logo




eISSN: 1643-3750

Get your full text copy in PDF

Pharmacokinetics of erythrocyte-bound daunorubicin in patients with acute leukemia

Oleksii A. Skorokhod, Tat’yana Ts. Garmaeva, Victor M. Vitvitsky, Valentin G. Isaev, Elena N. Parovichnikova, Valerii G. Savchenko, Fazoil I. Ataullakhanov

Med Sci Monit 2004; 10(4): PI55-64

ID: 11632


Background:The objective of the present study was in vitro and in vivo investigation of erythrocytes as vehicles for anthracycline antibiotics.Material/Methods: The kinetics of daunorubicin binding with erythrocytes was studied in blood and in washed erythrocyte suspensions from healthy donors and patients with acute leukemia. The effect of daunorubicin on erythrocyte deformability was studied using cell filtration through membranes with 3 Km-diameter cylindrical pores. Erythrocyte-bound daunorubicin (EBD), prepared by equilibrating anticoagulated autologous blood with the antibiotic, was administered (45 or 60 mg/m2 body surface) to 14 leukemic patients as part of the 7+3 or RACOP courses. The pharmacokinetics of daunorubicin and its tolerability were studied.Results: Human erythrocytes bound daunorubicin (rubomycin) in citrated whole blood or in washed saline suspension. The equilibrium erythrocyte/medium daunorubicin concentration ratios (attained in 30–60 min at 37°C) averaged 2.9I0.5 (n=13) in blood and 5.7I0.6 (n=8) in suspension (p<0.001), without any significant difference between the erythrocytes of donors and patients with acute drug-resistant leukemia or leukemic relapses. Incubation of patient blood with daunorubicin (0.5 mg/ml cells) did not affect erythrocyte deformability (filterability). After intravenous administration, the peak drug concentration and its elimination rate were lower for EBD than for free daunorubicin. The patients tolerated EBD better than its standard free form. In nine patients who received three EBD infusions, side effects were less frequent than in those treated with free daunorubicin.
Conclusions:     Our results indicate that daunorubicin-loaded erythrocytes are promising for clinical application and deserve further clinical study.

This paper has been published under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
I agree